1. Search Result
Search Result
Results for "

thrombus formation

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Screening Libraries

2

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10267

    PD-0348292

    Factor Xa Cardiovascular Disease
    Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a Ki value of 0.32 nM. Eribaxaban reduces thrombus formation .
    Eribaxaban
  • HY-W654264

    Endogenous Metabolite Integrin Cardiovascular Disease
    2-Methylbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. 2-Methylbutyrylcarnitine (chloride) enhances platelet hyperreactivity and thrombus formation in mice. 2-Methylbutyrylcarnitine (chloride) is a branched-chain acylcarnitine .
    2-Methylbutyrylcarnitine chloride
  • HY-13965
    Parmodulin 2
    2 Publications Verification

    ML161

    Protease Activated Receptor (PAR) Cardiovascular Disease
    Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC50 of 0.26 μM . Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo .
    Parmodulin 2
  • HY-114086

    PDI Cardiovascular Disease
    ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC50 of 250 nM. ML359 can prevent thrombus formation in vivo .
    ML359
  • HY-111447

    NADPH Oxidase Apoptosis Cardiovascular Disease Cancer
    VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins .
    VAS 3947
  • HY-116400

    Calcium Channel Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    BN 50341 is an orally active anticalcic agent and a benzazepine derivative. BN 50341 decreases the in vivo electrically induced thrombus formation in rat or guinea-pig artery and can be utilized in cardiovascular research .
    BN 50341
  • HY-101727

    Calcium Channel 5-HT Receptor Cardiovascular Disease
    Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca 2+/5-HT2 antagonist on thrombus formation in vivo and on platelet aggregation in vitro.
    Nexopamil racemate
  • HY-116281

    Prostaglandin Receptor Cardiovascular Disease
    ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .
    ICI D1542
  • HY-P991124

    Factor XI Cardiovascular Disease
    Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
    Cenvacibart
  • HY-167736

    Others Others
    (2R)-Naroparcil is an isomer of Naroparcil, a 4-methylumbelliferyl beta-D-xyloside analog that plays a role in promoting vascular smooth muscle cell proliferation and has been shown to inhibit thrombus formation in the Wessler slough model.
    (2R)-Naroparcil
  • HY-170655

    PDI Integrin Cardiovascular Disease
    PDI-IN-4 (Compound 14d) is an inhibitor of protein disulfide isomerase, with an IC50 value of 0.48 μM. PDI-IN-4 suppresses platelet aggregation and thrombus formation by attenuating GPIIb/IIIa activation without significantly causing cytotoxicity. PDI-IN-4 can be used in research on thrombosis .
    PDI-IN-4
  • HY-P3082

    Endogenous Metabolite Cardiovascular Disease
    SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
    SKF 106760
  • HY-123400A

    iso-DTTX30; iso-DT-TX 30 SE

    Prostaglandin Receptor Cardiovascular Disease
    Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
    iso-Samixogrel
  • HY-107588
    TC-I 15
    1 Publications Verification

    Integrin Cardiovascular Disease
    TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
    TC-I 15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: